Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionbenzodiazepine receptor binding

RIMBP3 RIMBP3C RIMBP3B

1.94e-0651173GO:0030156
GeneOntologyMolecularFunctioncalcium-induced calcium release activity

RYR2 RYR3 PKD2

3.87e-0661173GO:0048763
GeneOntologyMolecularFunction3',5'-cGMP-inhibited cyclic-nucleotide phosphodiesterase activity

PDE3A PDE3B

3.40e-0521172GO:0004119
GeneOntologyMolecularFunctionintracellularly gated calcium channel activity

RYR2 RYR3 PKD2

1.50e-04181173GO:0015278
GeneOntologyMolecularFunctionminus-end-directed microtubule motor activity

DNHD1 DNAH6 DNAH9

1.50e-04181173GO:0008569
GeneOntologyMolecularFunctionmechanosensitive monoatomic ion channel activity

PIEZO1 PIEZO2 TMEM63A

1.50e-04181173GO:0008381
GeneOntologyMolecularFunctionryanodine-sensitive calcium-release channel activity

RYR2 RYR3

2.03e-0441172GO:0005219
GeneOntologyMolecularFunction3',5'-cyclic-AMP phosphodiesterase activity

PDE3A PDE3B PDE6A

2.78e-04221173GO:0004115
GeneOntologyMolecularFunction3',5'-cyclic-GMP phosphodiesterase activity

PDE3A PDE3B PDE6A

3.63e-04241173GO:0047555
GeneOntologyMolecularFunction3',5'-cyclic-nucleotide phosphodiesterase activity

PDE3A PDE3B PDE6A

4.10e-04251173GO:0004114
GeneOntologyMolecularFunctioncyclic-nucleotide phosphodiesterase activity

PDE3A PDE3B PDE6A

5.18e-04271173GO:0004112
GeneOntologyMolecularFunctionbitter taste receptor activity

TAS2R8 TAS2R36 TAS2R20

5.18e-04271173GO:0033038
GeneOntologyMolecularFunctionDNA-binding transcription factor activity, RNA polymerase II-specific

PDE3A ZNF585A ZNF789 ZNF423 ZNF224 ADNP ZNF546 MEOX1 ZNF707 NFE2L3 ZNF547 ZNF341 OSR1 ZNF616 ZNF766 ZNF700 EMX2 ZBTB18 ST18

5.43e-04141211719GO:0000981
GeneOntologyMolecularFunctionphosphatidylinositol binding

ARHGAP32 SNX24 SNX29 SNX6 PIK3C2B CLVS2 SNX15 MCF2L

5.52e-043161178GO:0035091
GeneOntologyMolecularFunctiondynein light intermediate chain binding

DNHD1 DNAH6 DNAH9

5.77e-04281173GO:0051959
GeneOntologyMolecularFunctioncytoskeletal motor activity

DNHD1 APPBP2 MYO5B DNAH6 DNAH9

6.55e-041181175GO:0003774
GeneOntologyMolecularFunctionmicrotubule motor activity

DNHD1 APPBP2 DNAH6 DNAH9

7.62e-04701174GO:0003777
GeneOntologyMolecularFunctionligand-gated calcium channel activity

RYR2 RYR3 PKD2

7.82e-04311173GO:0099604
GeneOntologyMolecularFunctiongated channel activity

CHRNA6 PIEZO1 RYR2 RYR3 PIEZO2 KCND2 PKD2 TMEM63A

7.92e-043341178GO:0022836
GeneOntologyMolecularFunctionmonoatomic cation channel activity

CHRNA6 PIEZO1 RYR2 RYR3 PIEZO2 KCND2 PKD2 TMEM63A

9.40e-043431178GO:0005261
GeneOntologyMolecularFunctionintracellularly ligand-gated monoatomic ion channel activity

RYR2 RYR3 PKD2

9.41e-04331173GO:0005217
GeneOntologyMolecularFunctiontaste receptor activity

TAS2R8 TAS2R36 TAS2R20

9.41e-04331173GO:0008527
GeneOntologyMolecularFunctiondynein intermediate chain binding

DNHD1 DNAH6 DNAH9

1.32e-03371173GO:0045505
GeneOntologyMolecularFunctionligand-gated monoatomic cation channel activity

CHRNA6 RYR2 RYR3 PKD2 TMEM63A

1.41e-031401175GO:0099094
GeneOntologyMolecularFunctionphospholipid binding

ARHGAP32 SNX24 ANXA4 SNX29 TIAM1 SNX6 PIK3C2B CLVS2 SNX15 MCF2L

1.44e-0354811710GO:0005543
GeneOntologyMolecularFunctionchromatin-protein adaptor activity

MSL3 USP15 RAD17

1.78e-03411173GO:0140463
GeneOntologyMolecularFunctionRNA polymerase II transcription regulatory region sequence-specific DNA binding

ZNF585A ZNF789 ZNF423 ZNF224 ADNP ZNF546 MEOX1 ZNF707 NFE2L3 ZNF547 AGO1 ZNF341 OSR1 ZNF616 ZNF766 ZNF700 EMX2 ST18

2.05e-03145911718GO:0000977
GeneOntologyCellularComponentMon1-Ccz1 complex

CCZ1B CCZ1

2.97e-0451152GO:0035658
GeneOntologyCellularComponentguanyl-nucleotide exchange factor complex

CCZ1B PDE3B CCZ1

3.02e-04241153GO:0032045
GeneOntologyCellularComponentaxonemal dynein complex

DNHD1 DNAH6 DNAH9

3.42e-04251153GO:0005858
GeneOntologyCellularComponentcilium

DNHD1 RPGRIP1 IFT27 PDE6A IRS1 CDK10 WDPCP CSNK1A1L TIAM1 CEP83 PKD2 TAS2R20 DNAH6 DNAH9

4.17e-0489811514GO:0005929
GeneOntologyCellularComponentmanchette

RIMBP3 RIMBP3C RIMBP3B

4.81e-04281153GO:0002177
DomainPX

ARHGAP32 SNX24 SNX29 SNX6 PIK3C2B SNX15

5.38e-07491156PF00787
DomainPX

ARHGAP32 SNX24 SNX29 SNX6 PIK3C2B SNX15

6.09e-07501156PS50195
Domain-

ARHGAP32 SNX24 SNX29 SNX6 PIK3C2B SNX15

6.87e-075111563.30.1520.10
DomainPhox

ARHGAP32 SNX24 SNX29 SNX6 PIK3C2B SNX15

7.72e-07521156IPR001683
DomainPIEZO

PIEZO1 PIEZO2

3.76e-0521152PF15917
DomainPiezo

PIEZO1 PIEZO2

3.76e-0521152IPR027272
DomainPiezo_RRas_bdg

PIEZO1 PIEZO2

3.76e-0521152PF12166
DomainDUF1712

CCZ1B CCZ1

3.76e-0521152PF08217
DomainPiezo_RRas-bd_dom

PIEZO1 PIEZO2

3.76e-0521152IPR031334
DomainDUF1712_fun

CCZ1B CCZ1

3.76e-0521152IPR013176
DomainPiezo_dom

PIEZO1 PIEZO2

3.76e-0521152IPR031805
DomainDynein_HC_stalk

DNHD1 DNAH6 DNAH9

7.88e-05141153IPR024743
DomainDynein_heavy_dom-2

DNHD1 DNAH6 DNAH9

7.88e-05141153IPR013602
DomainDHC_N2

DNHD1 DNAH6 DNAH9

7.88e-05141153PF08393
DomainMT

DNHD1 DNAH6 DNAH9

7.88e-05141153PF12777
Domainzf-C2H2

ZNF585A ZNF789 ZNF423 ZNF224 ADNP ZNF546 ZNF707 ZNF547 ZNF341 OSR1 ZNF616 ZNF766 ZNF700 ZBTB18

9.18e-0569311514PF00096
DomainZnf_C2H2/integrase_DNA-bd

ZNF585A ZNF789 ZNF423 ZNF224 ADNP ZNF546 ZNF707 ZNF547 ZNF341 OSR1 ZNF616 ZNF766 ZNF700 ZBTB18

9.32e-0569411514IPR013087
DomainDHC_fam

DNHD1 DNAH6 DNAH9

9.80e-05151153IPR026983
DomainDynein_heavy

DNHD1 DNAH6 DNAH9

9.80e-05151153PF03028
DomainDynein_heavy_dom

DNHD1 DNAH6 DNAH9

9.80e-05151153IPR004273
DomainRyanodine_rcpt

RYR2 RYR3

1.12e-0431152IPR003032
DomainRyanrecept_TM4-6

RYR2 RYR3

1.12e-0431152IPR009460
DomainRyR

RYR2 RYR3

1.12e-0431152PF02026
DomainRR_TM4-6

RYR2 RYR3

1.12e-0431152PF06459
DomainRyan_recept

RYR2 RYR3

1.12e-0431152IPR013333
DomainPX

SNX24 SNX29 PIK3C2B SNX15

1.53e-04441154SM00312
DomainArgonaute_N

AGO2 AGO1

2.24e-0441152IPR032474
DomainArgonaute_Mid_dom

AGO2 AGO1

2.24e-0441152IPR032473
DomainArgoL2

AGO2 AGO1

2.24e-0441152IPR032472
DomainArgoN

AGO2 AGO1

2.24e-0441152PF16486
DomainArgoMid

AGO2 AGO1

2.24e-0441152PF16487
DomainArgoL2

AGO2 AGO1

2.24e-0441152PF16488
DomainAAA

ABCF1 ATAD5 ABCD3 DNAH6 DNAH9 RAD17

2.67e-041441156SM00382
DomainAAA+_ATPase

ABCF1 ATAD5 ABCD3 DNAH6 DNAH9 RAD17

2.67e-041441156IPR003593
DomainPDEase_I

PDE3A PDE3B PDE6A

2.79e-04211153PF00233
DomainPDEASE_I

PDE3A PDE3B PDE6A

2.79e-04211153PS00126
DomainPDEase_CS

PDE3A PDE3B PDE6A

2.79e-04211153IPR023174
Domain-

ZNF585A ZNF789 ZNF423 ZNF224 ZNF546 ZNF707 ZNF547 ZNF341 OSR1 ZNF616 ZNF766 ZNF700 ZBTB18

2.80e-04679115133.30.160.60
DomainZINC_FINGER_C2H2_2

ZNF585A ZNF789 ZNF423 ZNF224 ADNP ZNF546 ZNF707 ZNF547 ZNF341 OSR1 ZNF616 ZNF766 ZNF700 ZBTB18

2.92e-0477511514PS50157
DomainZINC_FINGER_C2H2_1

ZNF585A ZNF789 ZNF423 ZNF224 ADNP ZNF546 ZNF707 ZNF547 ZNF341 OSR1 ZNF616 ZNF766 ZNF700 ZBTB18

3.00e-0477711514PS00028
Domain-

PDE3A PDE3B PDE6A

3.22e-042211531.10.1300.10
DomainPDEase_catalytic_dom

PDE3A PDE3B PDE6A

3.68e-04231153IPR002073
DomainDUF1785

AGO2 AGO1

3.71e-0451152SM01163
DomainKRAB

ZNF585A ZNF789 ZNF224 ZNF546 ZNF707 ZNF547 ZNF616 ZNF766 ZNF700

3.73e-043581159PS50805
DomainKRAB

ZNF585A ZNF789 ZNF224 ZNF546 ZNF707 ZNF547 ZNF616 ZNF766 ZNF700

3.73e-043581159PF01352
DomainZnf_C2H2-like

ZNF585A ZNF789 ZNF423 ZNF224 ADNP ZNF546 ZNF707 ZNF547 ZNF341 OSR1 ZNF616 ZNF766 ZNF700 ZBTB18

3.83e-0479611514IPR015880
DomainHD/PDEase_dom

PDE3A PDE3B PDE6A

4.19e-04241153IPR003607
DomainHDc

PDE3A PDE3B PDE6A

4.19e-04241153SM00471
DomainZnf_C2H2

ZNF585A ZNF789 ZNF423 ZNF224 ADNP ZNF546 ZNF707 ZNF547 ZNF341 OSR1 ZNF616 ZNF766 ZNF700 ZBTB18

4.28e-0480511514IPR007087
DomainZnF_C2H2

ZNF585A ZNF789 ZNF423 ZNF224 ADNP ZNF546 ZNF707 ZNF547 ZNF341 OSR1 ZNF616 ZNF766 ZNF700 ZBTB18

4.44e-0480811514SM00355
DomainKRAB

ZNF585A ZNF789 ZNF224 ZNF546 ZNF707 ZNF547 ZNF616 ZNF766 ZNF700

4.65e-043691159SM00349
DomainKRAB

ZNF585A ZNF789 ZNF224 ZNF546 ZNF707 ZNF547 ZNF616 ZNF766 ZNF700

4.74e-043701159IPR001909
DomainRIH_assoc-dom

RYR2 RYR3

5.55e-0461152IPR013662
DomainIns145_P3_rec

RYR2 RYR3

5.55e-0461152PF08709
DomainRIH_assoc

RYR2 RYR3

5.55e-0461152PF08454
DomainArgoL1

AGO2 AGO1

5.55e-0461152PF08699
DomainRIH_dom

RYR2 RYR3

5.55e-0461152IPR000699
DomainIns145_P3_rcpt

RYR2 RYR3

5.55e-0461152IPR014821
DomainRyanodine_recept-rel

RYR2 RYR3

5.55e-0461152IPR015925
DomainArgoL1

AGO2 AGO1

5.55e-0461152IPR014811
Domain-

RYR2 RYR3

5.55e-04611521.25.10.30
DomainRYDR_ITPR

RYR2 RYR3

5.55e-0461152PF01365
Domainzf-C2H2_6

ZNF789 ZNF423 ZNF224 ZNF546 OSR1 ZNF616 ZNF766 ZNF700

7.28e-043141158PF13912
DomainPIWI

AGO2 AGO1

1.03e-0381152PS50822
DomainPiwi

AGO2 AGO1

1.03e-0381152SM00950
DomainPiwi

AGO2 AGO1

1.03e-0381152PF02171
DomainPiwi

AGO2 AGO1

1.03e-0381152IPR003165
DomainARM-type_fold

USP34 VIRMA RYR3 CSE1L PIK3C2B CLTC AP1G2 IPO11

1.19e-033391158IPR016024
Domain-

GBE1 LCTL GLB1

1.29e-033511533.20.20.80
DomainPAZ

AGO2 AGO1

1.32e-0391152PS50821
DomainPAZ

AGO2 AGO1

1.32e-0391152SM00949
DomainPAZ

AGO2 AGO1

1.32e-0391152PF02170
DomainPAZ_dom

AGO2 AGO1

1.32e-0391152IPR003100
DomainSH3_9

ARHGAP32 RIMBP3 RIMBP3C RIMBP3B

1.37e-03781154PF14604
DomainMIR

RYR2 RYR3

1.64e-03101152PF02815
DomainMIR_motif

RYR2 RYR3

1.64e-03101152IPR016093
DomainMIR

RYR2 RYR3

1.64e-03101152PS50919
DomainMIR

RYR2 RYR3

1.64e-03101152SM00472
DomainGlyco_hydro_catalytic_dom

GBE1 LCTL GLB1

1.64e-03381153IPR013781
DomainSH3_2

RIMBP3 RIMBP3C MCF2L RIMBP3B

1.96e-03861154PF07653
DomainSH3_2

RIMBP3 RIMBP3C MCF2L RIMBP3B

1.96e-03861154IPR011511
DomainDynein_heavy_chain_D4_dom

DNAH6 DNAH9

3.26e-03141152IPR024317
DomainIMPORTIN_B_NT

CSE1L IPO11

3.26e-03141152PS50166
DomainATPase_dyneun-rel_AAA

DNAH6 DNAH9

3.26e-03141152IPR011704
DomainAAA_8

DNAH6 DNAH9

3.26e-03141152PF12780
DomainAAA_5

DNAH6 DNAH9

3.26e-03141152PF07728
DomainIBN_N

CSE1L IPO11

3.74e-03151152PF03810
DomainGlycoside_hydrolase_SF

GBE1 LCTL GLB1

4.26e-03531153IPR017853
DomainIBN_N

CSE1L IPO11

4.26e-03161152SM00913
DomainImportin-beta_N

CSE1L IPO11

4.81e-03171152IPR001494
PathwayWP_FRAGILE_X_SYNDROME

ARHGAP32 RAP1GAP AGO2 TECR KCND2 CLTC ABCD3

6.98e-06121837M39804
PathwayWP_CILIOPATHIES

RPGRIP1 IFT27 ZNF423 WDPCP CEP83 PKD2 DNAH6

1.04e-04184837M39880
Pubmed

RIM-BP3 is a manchette-associated protein essential for spermiogenesis.

RIMBP3 RIMBP3C RIMBP3B

1.52e-074118319091768
Pubmed

Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.

APPBP2 ZNF423 URB2 VIRMA ADCY2 UNC5A CLTC PPIP5K1 MCF2L USP15 ST18

1.54e-074071181112693553
Pubmed

Structure and evolution of RIM-BP genes: identification of a novel family member.

RIMBP3 RIMBP3C RIMBP3B

3.79e-075118317855024
Pubmed

An organelle-specific protein landscape identifies novel diseases and molecular mechanisms.

RPGRIP1 IFT27 ABCF1 MYO5B ACTR10 CSE1L TM9SF2 GLB1 TIAM1 PKD2 ABCD3 PISD VSIG8 PAN3 USP15 IPO11

1.04e-0513211181627173435
Pubmed

Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases.

PDE3A PDE3B PDE6A

1.06e-051311838557689
Pubmed

Phosphodiesterase type 3A (PDE3A), but not type 3B (PDE3B), contributes to the adverse cardiac remodeling induced by pressure overload.

PDE3A PDE3B

1.14e-052118231051182
Pubmed

Reduced Expression of Argonaute 1, Argonaute 2, and TRBP Changes Levels and Intracellular Distribution of RNAi Factors.

AGO2 AGO1

1.14e-052118226242502
Pubmed

Pde3a and Pde3b regulation of murine pulmonary artery smooth muscle cell growth and metabolism.

PDE3A PDE3B

1.14e-052118239435735
Pubmed

[Feeling the pressure? Identification of two proteins activated by mechanical forces].

PIEZO1 PIEZO2

1.14e-052118221299953
Pubmed

Altered ryanodine receptor expression in mild cognitive impairment and Alzheimer's disease.

RYR2 RYR3

1.14e-052118221531043
Pubmed

Piezo1-dependent stretch-activated channels are inhibited by Polycystin-2 in renal tubular epithelial cells.

PIEZO1 PKD2

1.14e-052118224157948
Pubmed

Differential regulation of gene expression and insulin-induced activation of phosphodiesterase 3B in adipocytes of lean insulin-resistant IRS-1 (-/-) mice.

PDE3B IRS1

1.14e-052118212213348
Pubmed

Modulation of calcium signalling by dominant negative splice variant of ryanodine receptor subtype 3 in native smooth muscle cells.

RYR2 RYR3

1.14e-052118216678258
Pubmed

Piezo1 expression in chondrocytes controls endochondral ossification and osteoarthritis development.

PIEZO1 PIEZO2

1.14e-052118238395992
Pubmed

Differential expression of PIEZO1 and PIEZO2 mechanosensitive channels in ocular tissues implicates diverse functional roles.

PIEZO1 PIEZO2

1.14e-052118237820892
Pubmed

Mechanisms of mechanotransduction and physiological roles of PIEZO channels.

PIEZO1 PIEZO2

1.14e-052118239251883
Pubmed

Immunolocalization of the mechanogated ion channels PIEZO1 and PIEZO2 in human and mouse dental pulp and periodontal ligament.

PIEZO1 PIEZO2

1.14e-052118237975162
Pubmed

Association study of AGO1 and AGO2 genes polymorphisms with recurrent pregnancy loss.

AGO2 AGO1

1.14e-052118231666609
Pubmed

Transduction of Repetitive Mechanical Stimuli by Piezo1 and Piezo2 Ion Channels.

PIEZO1 PIEZO2

1.14e-052118228636944
Pubmed

A pathophysiological role of PDE3 in allergic airway inflammation.

PDE3A PDE3B

1.14e-052118229367458
Pubmed

Piezo channels: from structure to function.

PIEZO1 PIEZO2

1.14e-052118225037583
Pubmed

Tissue-specific alternative splicing of mouse brain type ryanodine receptor/calcium release channel mRNA.

RYR2 RYR3

1.14e-05211828898078
Pubmed

Alternative RISC assembly: binding and repression of microRNA-mRNA duplexes by human Ago proteins.

AGO2 AGO1

1.14e-052118223019594
Pubmed

Piezo proteins: incidence and abundance in the enteric nervous system. Is there a link with mechanosensitivity?

PIEZO1 PIEZO2

1.14e-052118230324494
Pubmed

Involvement of AGO1 and AGO2 in mammalian transcriptional silencing.

AGO2 AGO1

1.14e-052118216936728
Pubmed

Human eukaryotic initiation factor EIF2C1 gene: cDNA sequence, genomic organization, localization to chromosomal bands 1p34-p35, and expression.

AGO2 AGO1

1.14e-052118210534406
Pubmed

Phosphodiesterase 3A (PDE3A) deletion suppresses proliferation of cultured murine vascular smooth muscle cells (VSMCs) via inhibition of mitogen-activated protein kinase (MAPK) signaling and alterations in critical cell cycle regulatory proteins.

PDE3A PDE3B

1.14e-052118221632535
Pubmed

Argonaute Family Protein Expression in Normal Tissue and Cancer Entities.

AGO2 AGO1

1.14e-052118227518285
Pubmed

Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients.

ADCY2 MTRR

1.14e-052118225815774
Pubmed

The mouse sino-atrial node expresses both the type 2 and type 3 Ca(2+) release channels/ryanodine receptors.

RYR2 RYR3

1.14e-052118214550562
Pubmed

Regulation of ryanodine receptor-dependent calcium signaling by polycystin-2.

RYR2 PKD2

1.14e-052118217404231
Pubmed

Mechanosensitive channels: in touch with Piezo.

PIEZO1 PIEZO2

1.14e-052118221056836
Pubmed

Loss of stretch-activated channels, PIEZOs, accelerates non-small cell lung cancer progression and cell migration.

PIEZO1 PIEZO2

1.14e-052118230745454
Pubmed

The role of PIEZO ion channels in the musculoskeletal system.

PIEZO1 PIEZO2

1.14e-052118236717101
Pubmed

Astrocytes in the optic nerve head express putative mechanosensitive channels.

PIEZO1 PIEZO2

1.14e-052118226236150
Pubmed

Association of Polymorphic Variants in Argonaute Genes with Depression Risk in a Polish Population.

AGO2 AGO1

1.14e-052118236142498
Pubmed

Touch, Tension, and Transduction - The Function and Regulation of Piezo Ion Channels.

PIEZO1 PIEZO2

1.14e-052118227743844
Pubmed

Axonal and Glial PIEZO1 and PIEZO2 Immunoreactivity in Human Clitoral Krause's Corpuscles.

PIEZO1 PIEZO2

1.14e-052118238928429
Pubmed

A hydrophobic gate in the inner pore helix is the major determinant of inactivation in mechanosensitive Piezo channels.

PIEZO1 PIEZO2

1.14e-052118230628892
Pubmed

Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma.

AGO2 AGO1

1.14e-052118222858679
Pubmed

Piezo1 ion channel pore properties are dictated by C-terminal region.

PIEZO1 PIEZO2

1.14e-052118226008989
Pubmed

Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice.

PDE3A PDE3B

1.14e-052118217482796
Pubmed

Single-stranded antisense siRNAs guide target RNA cleavage in RNAi.

AGO2 AGO1

1.14e-052118212230974
Pubmed

Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels.

PIEZO1 PIEZO2

1.14e-052118220813920
Pubmed

Decreased expression of ryanodine receptors alters calcium-induced calcium release mechanism in mdx duodenal myocytes.

RYR2 RYR3

1.14e-052118214985349
Pubmed

Polymorphisms and expression of genes encoding Argonautes 1 and 2 in autoimmune thyroid diseases.

AGO2 AGO1

1.14e-052118229256262
Pubmed

A Plug-and-Latch Mechanism for Gating the Mechanosensitive Piezo Channel.

PIEZO1 PIEZO2

1.14e-052118232142647
Pubmed

Targeted disruption of PDE3B, but not PDE3A, protects murine heart from ischemia/reperfusion injury.

PDE3A PDE3B

1.14e-052118225877153
Pubmed

Functional roles for PIEZO1 and PIEZO2 in urothelial mechanotransduction and lower urinary tract interoception.

PIEZO1 PIEZO2

1.14e-052118234464353
Pubmed

mRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer.

AGO2 AGO1

1.14e-052118219723326
Pubmed

Evaluation of Argonaute protein as a predictive marker for human clear cell renal cell carcinoma.

AGO2 AGO1

1.14e-052118223696926
Pubmed

Ago1 and Ago2 differentially affect cell proliferation, motility and apoptosis when overexpressed in SH-SY5Y neuroblastoma cells.

AGO2 AGO1

1.14e-052118221846468
Pubmed

The association of AGO1 (rs595961G>A, rs636832A>G) and AGO2 (rs11996715C>A, rs2292779C>G, rs4961280C>A) polymorphisms and risk of recurrent implantation failure.

AGO2 AGO1

1.14e-052118231724726
Pubmed

Argonaute proteins couple chromatin silencing to alternative splicing.

AGO2 AGO1

1.14e-052118222961379
Pubmed

Integrative characterization of germ cell-specific genes from mouse spermatocyte UniGene library.

RIMBP3 RIMBP3C RIMBP3B

1.35e-0514118317662146
Pubmed

Identification of potential protein interactors of Lrrk2.

AGO2 AGO1 CLTC

1.68e-0515118317400507
Pubmed

Prediction of the coding sequences of unidentified human genes. XI. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.

USP34 ARHGAP32 ZNF423 ADNP TMEM63A

2.52e-0510111859872452
Pubmed

KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.

ARHGAP32 RAP1GAP ABCF1 AGO2 MYO5B TECR SPECC1L VIRMA NUAK2 CSNK1A1L CSE1L AGO1 SBF1 CLTC ABCD3 DNAH6

2.77e-0514311181637142655
Pubmed

Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.

USP34 RAP1GAP ABCF1 HLA-DRA ZNF423 ZNF224 TUBGCP5 RYR3 DMAP1 NFE2L3 UBA7 TIAM1 SNX6 CLTC ST18

3.09e-0512851181535914814
Pubmed

Turning catalytically inactive human Argonaute proteins into active slicer enzymes.

AGO2 AGO1

3.42e-053118223665583
Pubmed

Type 1 and type 3 ryanodine receptors are selectively involved in muscarinic antinociception in mice: an antisense study.

RYR2 RYR3

3.42e-053118218403125
Pubmed

Heterogeneous gene expression and functional activity of ryanodine receptors in resistance and conduit pulmonary as well as mesenteric artery smooth muscle cells.

RYR2 RYR3

3.42e-053118218434746
Pubmed

A Slicer-independent role for Argonaute 2 in hematopoiesis and the microRNA pathway.

AGO2 AGO1

3.42e-053118217626790
Pubmed

Control of Neuronal Ryanodine Receptor-Mediated Calcium Signaling by Calsenilin.

RYR2 RYR3

3.42e-053118229730765
Pubmed

Molecular cloning and chromosomal assignment of the human homologue of the rat cGMP-inhibited phosphodiesterase 1 (PDE3A)--a gene involved in fat metabolism located at 11p 15.1.

PDE3A PDE3B

3.42e-05311828921398
Pubmed

PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation.

CCZ1B CCZ1

3.42e-053118232160108
Pubmed

SPRY domains in ryanodine receptors (Ca(2+)-release channels).

RYR2 RYR3

3.42e-05311829204703
Pubmed

The ryanodine receptor/calcium channel genes are widely and differentially expressed in murine brain and peripheral tissues.

RYR2 RYR3

3.42e-05311827876312
Pubmed

The roles of individual mammalian argonautes in RNA interference in vivo.

AGO2 AGO1

3.42e-053118224992693
Pubmed

Ryanodine receptors are expressed in epidermal keratinocytes and associated with keratinocyte differentiation and epidermal permeability barrier homeostasis.

RYR2 RYR3

3.42e-053118221881589
Pubmed

Argonaute 2/RISC resides in sites of mammalian mRNA decay known as cytoplasmic bodies.

AGO2 AGO1

3.42e-053118215908945
Pubmed

Mechanically Activated Piezo Channels Mediate Touch and Suppress Acute Mechanical Pain Response in Mice.

PIEZO1 PIEZO2

3.42e-053118230726728
Pubmed

Isoform-dependent formation of heteromeric Ca2+ release channels (ryanodine receptors).

RYR2 RYR3

3.42e-053118212213830
Pubmed

Exploring Piezo1, Piezo2, and TMEM150C in human brain tissues and their correlation with brain biomechanical characteristics.

PIEZO1 PIEZO2

3.42e-053118238124148
Pubmed

Expression of the ryanodine receptor type 3 calcium release channel during development and differentiation of mammalian skeletal muscle cells.

RYR2 RYR3

3.42e-05311829242641
Pubmed

Bidirectional coupling between ryanodine receptors and Ca2+ release-activated Ca2+ (CRAC) channel machinery sustains store-operated Ca2+ entry in human T lymphocytes.

RYR2 RYR3

3.42e-053118222948152
Pubmed

Developmental changes in expression of the three ryanodine receptor mRNAs in the mouse brain.

RYR2 RYR3

3.42e-053118210788707
Pubmed

Ago1 Interacts with RNA polymerase II and binds to the promoters of actively transcribed genes in human cancer cells.

AGO2 AGO1

3.42e-053118224086155
Pubmed

RYR2 proteins contribute to the formation of Ca(2+) sparks in smooth muscle.

RYR2 RYR3

3.42e-053118215024040
Pubmed

Myotubularin related protein-2 and its phospholipid substrate PIP2 control Piezo2-mediated mechanotransduction in peripheral sensory neurons.

PIEZO1 PIEZO2

3.42e-053118229521261
Pubmed

PIEZOs mediate neuronal sensing of blood pressure and the baroreceptor reflex.

PIEZO1 PIEZO2

3.42e-053118230361375
Pubmed

Calcineurin upregulates local Ca(2+) signaling through ryanodine receptor-1 in airway smooth muscle cells.

RYR2 RYR3

3.42e-053118225239916
Pubmed

Piezo1, a mechanically activated ion channel, is required for vascular development in mice.

PIEZO1 PIEZO2

3.42e-053118224958852
Pubmed

Ca(2+)-induced Ca2+ release in myocytes from dyspedic mice lacking the type-1 ryanodine receptor.

RYR2 RYR3

3.42e-05311827621815
Pubmed

A gene-specific cerebral types 1, 2, and 3 RyR protein knockdown induces an antidepressant-like effect in mice.

RYR2 RYR3

3.42e-053118218643873
Pubmed

Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2).

RYR2 RYR3

3.42e-053118211159936
Pubmed

Labeling PIEZO2 activity in the peripheral nervous system.

PIEZO1 PIEZO2

3.42e-053118237321223
Pubmed

Impact of phosphodiesterases PDE3 and PDE4 on 5-hydroxytryptamine receptor4-mediated increase of cAMP in human atrial fibrillation.

PDE3A PDE3B

3.42e-053118232949251
Pubmed

A conserved motif in Argonaute-interacting proteins mediates functional interactions through the Argonaute PIWI domain.

AGO2 AGO1

3.42e-053118217891150
Pubmed

Argonaute2 is the catalytic engine of mammalian RNAi.

AGO2 AGO1

3.42e-053118215284456
Pubmed

Distinct passenger strand and mRNA cleavage activities of human Argonaute proteins.

AGO2 AGO1

3.42e-053118219946268
Pubmed

Molecular identification of the ryanodine receptor pore-forming segment.

RYR2 RYR3

3.42e-053118210473538
Pubmed

Chromosomal localization of murine ryanodine receptor genes RYR1, RYR2, and RYR3 by in situ hybridization.

RYR2 RYR3

3.42e-05311827959768
Pubmed

Hepatic Ago2-mediated RNA silencing controls energy metabolism linked to AMPK activation and obesity-associated pathophysiology.

AGO2 AGO1

3.42e-053118230201950
Pubmed

The organization of proteins in the human red blood cell membrane. A review.

RYR2 RYR3

3.42e-05311824600883
Pubmed

Mechanical forces couple bone matrix mineralization with inhibition of angiogenesis to limit adolescent bone growth.

PIEZO1 PIEZO2

3.42e-053118235650194
Pubmed

Regulation of mouse egg activation: presence of ryanodine receptors and effects of microinjected ryanodine and cyclic ADP ribose on uninseminated and inseminated eggs.

RYR2 RYR3

3.42e-05311827635066
Pubmed

Dorsal root ganglion axon bifurcation tolerates increased cyclic GMP levels: the role of phosphodiesterase 2A and scavenger receptor Npr3.

PDE3A PDE3B PDE6A

4.84e-0521118327740716
Pubmed

Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals.

PDE3A PDE3B IRS1

4.84e-0521118322479202
Pubmed

PRDM16 determines specification of ventricular cardiomyocytes by suppressing alternative cell fates.

PDE3A RYR3 KCND2

4.84e-0521118339304345
InteractionPUDP interactions

USP34 ARHGAP32 HPS3 SBF1 CCZ1 AP1G2 PPIP5K1

5.51e-08621137int:PUDP
InteractionSULT1C4 interactions

ARHGAP32 HPS3 CSE1L SBF1 SULT1C2 CCZ1 RAD17

2.86e-061101137int:SULT1C4
InteractionPLEKHG7 interactions

USP34 ADNP SNX6 CCZ1 AP1G2 PPIP5K1 RAD17

2.20e-051501137int:PLEKHG7
InteractionCRYBB3 interactions

ARHGAP32 SBF1 AP1G2 PPIP5K1 RAD17

2.75e-05631135int:CRYBB3
GeneFamilySorting nexins|PX-BAR domain containing

SNX24 SNX29 SNX6 SNX15

8.15e-0629814754
GeneFamilyZinc fingers C2H2-type|ZF class homeoboxes and pseudogenes

ZNF585A ZNF789 ZNF423 ZNF224 ZNF546 ZNF707 ZNF547 ZNF341 OSR1 ZNF616 ZNF766 ZNF700 ZBTB18

1.70e-05718811328
GeneFamilyRyanodine receptors|Protein phosphatase 1 regulatory subunits

RYR2 RYR3

5.93e-053812287
GeneFamilyPhosphodiesterases

PDE3A PDE3B PDE6A

1.64e-0424813681
GeneFamilyArgonaute/PIWI family

AGO2 AGO1

5.45e-048812408
GeneFamilyTaste 2 receptors

TAS2R8 TAS2R36 TAS2R20

7.05e-04398131162
GeneFamilyDyneins, axonemal

DNAH6 DNAH9

2.58e-0317812536
GeneFamilyBardet-Biedl syndrome associated|BBSome

IFT27 WDPCP

3.94e-0321812980
ToppCellMS-Treg-exh_CD4|MS / Condition, Cell_class and T cell subcluster

DYM SNX24 SPECC1L DMAP1 MTRR VSIG8 ZBTB18

7.71e-071921177c6722bf142c84ccedd99c1a3344085aecb4cbab4
ToppCellfacs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FAT4 RYR2 RYR3 PIEZO2 ST18 DNAH9

9.26e-0618411762cbed6462fea2622871bb7e49b0df3d984239281
ToppCellfacs-Thymus-Thymus_Epithelium-18m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FAT4 RYR2 RYR3 PIEZO2 ST18 DNAH9

9.26e-061841176ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCellfacs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FAT4 RYR2 RYR3 PIEZO2 ST18 DNAH9

9.26e-0618411762b19a8c5f823e00812908b23e66bb4e563278aff
ToppCellPCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature5_(6)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung

FAT4 PDE3B ZNF423 PIEZO2 TIAM1 RNF24

1.25e-051941176b1bb0f846d2865efdd9bc8842b16b9d069785882
ToppCellPCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature5_(6)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung

FAT4 PDE3B ZNF423 PIEZO2 TIAM1 RNF24

1.29e-0519511760e55fa5b3cbeb7baee3d4ac272a3bf80381ec937
ToppCellParenchymal-NucSeq-Stromal-Fibroblastic-Fibro_myofibroblast|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

FAT4 PDE3A PDE3B ADCY2 RYR2 PKD2

1.36e-0519711766d0d68d460243a0259ada93ebda40fa7b3088eeb
ToppCellNeuronal-Inhibitory-iA-iA_1(SST_PAX6)-SST-BAGE2|Neuronal / cells hierarchy compared to all cells using T-Statistic

CHRNA6 FAT4 PDE3A ZNF423 NDST4 RYR3

1.49e-05200117626f07d271e984f375145e4c10528fba44a5811e1
ToppCellNeuronal-Inhibitory-iA-iA_1(SST_PAX6)-SST-BAGE2-L1-2|Neuronal / cells hierarchy compared to all cells using T-Statistic

CHRNA6 FAT4 PDE3A ZNF423 NDST4 RYR3

1.49e-052001176c3637827ceba16b0d7956c280dd2ddbc8b1ba55e
ToppCellBronchial-NucSeq-Stromal-Chondrocytic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

PDE3A ADCY2 TIPARP PIEZO2 TIAM1 PKD2

1.49e-052001176b7b9441fa7ab0d43741a2ebd5ec1a48d537c6d47
ToppCellBronchial-NucSeq-Stromal-Chondrocytic-Chondrocyte|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

PDE3A ADCY2 TIPARP PIEZO2 TIAM1 PKD2

1.49e-0520011767c673ad0ea503ebd196579684d25d5f9e6a41030
ToppCell10x_3'_v2v3-Non-neoplastic-Myeloid-DC-cDC2-B|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

RPGRIP1 HLA-DRA LIPN NFE2L3 HAS1

5.76e-0515611750f54d62c0fc08bbdd5ac743b2d5d748c3d1e6ef9
ToppCellCOVID-19-kidney-Technical/muscle_(Mes)|kidney / Disease (COVID-19 only), tissue and cell type

NDST4 ADCY2 RYR2 KCND2 DNAH9

6.30e-0515911755335cbcdeaf2bbd0268bbfe0e45c8c0d288e640d
ToppCellPND03-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_prolif|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

PDE3B ATAD5 SNX6 CLTC AP1G2

6.30e-051591175c0e55f25271f788c08fa4b95186501fc27b2ec39
ToppCellE16.5-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2-AT2_mature|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

DNHD1 SNX29 CCZ1 CLTC VSIG8

6.89e-0516211758e0f03fcc25b2ea777e8478fbf771699cf93719c
ToppCellE16.5-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

DNHD1 SNX29 CCZ1 CLTC VSIG8

6.89e-051621175e0417f1242edf71934fe62bccc55c4678f7ff4ac
ToppCellwk_15-18-Mesenchymal-Myofibro_&_SMC-Myofibro_3|wk_15-18 / Celltypes from embryonic and fetal-stage human lung

FAT4 GPR85 URB2 ADCY2 SBF1

7.30e-051641175583dda853cee9491dbdcb228c23d8deadc20eb08
ToppCell356C-Myeloid-Dendritic-cDC_proliferating_2|Myeloid / Donor, Lineage, Cell class and subclass (all cells)

FMOD CSE1L LCTL DNAH9 IPO11

8.89e-051711175b113fbebb89056af0b9c775d2fb6552206a80467
ToppCell356C-Myeloid-Dendritic-cDC_proliferating_2|Dendritic / Donor, Lineage, Cell class and subclass (all cells)

FMOD CSE1L LCTL DNAH9 IPO11

9.91e-0517511757de1023161233b64f11e130881c742f4cf2bff65
ToppCellmetastatic_Brain-Endothelial_cells-Lymphatic_ECs|Endothelial_cells / Location, Cell class and cell subclass

IFT27 PDE3A FMOD NUAK2 EMX2

1.02e-04176117542541dfe20eb29625d47c0bb79bf3c21a2460340
ToppCellrenal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-Adaptive_/_Maladaptive_/_Repairing_Fibroblast|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

PDE3B ZNF423 ADCY2 RYR2 OSR1

1.05e-0417711759ec7f1e64312d26d434b3312b58386715dbad644
ToppCellrenal_papilla_nuclei-Adult_normal_reference-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

PDE3B ZNF423 ADCY2 RYR2 OSR1

1.05e-041771175016277dfd59b1793fddaaadc2b3f41622d76ce3a
ToppCellRSV-Healthy-0|RSV / Virus stimulation, Condition and Cluster

USP34 CCZ1B PDE3B ADNP SNX15

1.13e-041801175974044056e2f7e909cb11c6f6ca89e58bf95f7e5
ToppCellfacs-Bladder-nan-24m-Epithelial-bladder_mesenchymal_cell_(Car3+)|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FAT4 FMOD ZNF423 PIEZO1 CPT1C

1.13e-04180117512537d8a569faa69f474284d2c201475722b8ca1
ToppCellRSV-Healthy-0|Healthy / Virus stimulation, Condition and Cluster

USP34 CCZ1B PDE3B ADNP SNX15

1.13e-041801175703a1d0f9536af94d56757eb01221878d7b7fe61
ToppCellMid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1_SST_CXCL14|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

CHRNA6 FAT4 PDE3A NDST4 RYR3

1.13e-041801175b6efdb4d319ef6f87f559acd974e5a71b06a2322
ToppCellMid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Oligo-Oligodendrocyte-Oligo_L4-6_MOBP_COL18A1|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

KRT26 LIPN PIEZO2 ST18 TMEM63A

1.19e-041821175d524ad5cf00f05ee27c9db2ffa2d4e30a1e2e21a
ToppCellBAL-Severe-Myeloid-cDC-cDC-cDC_3|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

RPGRIP1 CHRNA6 HLA-DRA MAGEF1 TLR10

1.25e-0418411751c56378b3888c46258d446b47de4d6282fe74b0d
ToppCellBAL-Severe-Myeloid-cDC-cDC-cDC_3|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

RPGRIP1 CHRNA6 HLA-DRA MAGEF1 TLR10

1.25e-041841175a45980306c4e697a2703bed72a7b48fb23d942f4
ToppCellfacs-Brain_Non-Myeloid-Cerebellum-3m|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RPL37 ADCY2 RYR2 TIAM1 ZBTB18

1.29e-041851175cdd75abdaa1ecedfd2e636203b83a6ac1782f0c3
ToppCellLPS_only|World / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

GBE1 TIPARP NUAK2 RNF24 USP15

1.29e-041851175a72ccb147ca505880e2da8f6a70b9d570464a691
ToppCellMesenchymal-chondrocyte|World / Lineage, Cell type, age group and donor

FMOD KCTD4 IRS1 ADCY2 PIEZO2

1.39e-0418811757b1e3f8a941eaa68e89c562129a92314642eec66
ToppCellLPS-IL1RA+antiTNF-Endothelial|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

FAT4 PDE3B ZNF423 PIK3C2B MCF2L

1.53e-04192117504f5a2e3dd6beff027b89d66eefdd92036e041af
ToppCellLPS-IL1RA+antiTNF-Endothelial-Endothelial|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

FAT4 PDE3B ZNF423 PIK3C2B MCF2L

1.53e-041921175c07d7b40b2aa4eb27ac85801c014a656e2fd01dc
ToppCellfacs-Trachea-3m-Endothelial-endothelial_cell_of_trachea-tracheal_endothelial_cell-tracheal_endothelial_cell_l27|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

NUAK2 MEOX1 PIEZO2 PIK3C2B MCF2L

1.53e-0419211755012cc3ec0766f06af447463413422b484446c43
ToppCellfacs-Brain_Myeloid-Hippocampus-3m-Myeloid|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PDE3B TM9SF2 CLTC PAN3 HAS1

1.57e-04193117506b65110db974f4ef90d3511ff34428976a52c9c
ToppCellfacs-Brain_Myeloid-Hippocampus-3m-Myeloid-microglial_cell|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PDE3B TM9SF2 CLTC PAN3 HAS1

1.57e-0419311759c16032bc03df8760ae199e8f19fdafa4c3f1827
ToppCellLPS-antiTNF-Endothelial-Endothelial|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

FAT4 PDE3B ZNF423 PIK3C2B MCF2L

1.57e-04193117502f633b016ab19bfa65bfd0cf32f000549a62148
ToppCellfacs-Brain_Myeloid-Hippocampus-3m|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PDE3B TM9SF2 CLTC PAN3 HAS1

1.57e-041931175a4f91bca5eaa985982d33a528f7566ffde154d47
ToppCellLPS_only-Endothelial-Endothelial-Gen_Cap|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

FAT4 PDE3B ZNF423 PIK3C2B MCF2L

1.57e-041931175af5108260783e69a7d67896c5bf64f862525926d
ToppCellControl-Endothelial-Endothelial-Gen_Cap|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

FAT4 PDE3B ZNF423 PIEZO2 MCF2L

1.57e-041931175e1d546165dcc2392f540162206852c4717d7306f
ToppCellLPS-antiTNF-Endothelial|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

FAT4 PDE3B ZNF423 PIK3C2B MCF2L

1.57e-0419311755122b1ffba42de190061be34ecdc6176f84e56a3
ToppCellChildren_(3_yrs)-Mesenchymal-matrix_fibroblast_2_cell|Children_(3_yrs) / Lineage, Cell type, age group and donor

FAT4 PDE3A ZNF423 PIEZO2 OSR1

1.57e-0419311759ab47b360bee1d4f1092c2269e58acebe9584021
ToppCellfacs-Brain_Myeloid-Hippocampus-3m-Myeloid-nan|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PDE3B TM9SF2 CLTC PAN3 HAS1

1.57e-041931175b39d7feaac4ff8f7409cd3d15e8f3c6391367275
ToppCellfacs-Bladder-nan-3m-Epithelial-nan|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RPL37 ANXA4 NFE2L3 ABCD3 PAN3

1.60e-041941175e74cd8cf3763f6adbfd1c269a886a806049714cf
ToppCellFetal_29-31_weeks-Mesenchymal-matrix_fibroblast_1_cell|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

FAT4 PDE3B ADCY2 RYR2 PIEZO2

1.60e-041941175011e14d9ed1393275f892060e7708ffadcd0767f
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Epithelial|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

MYO5B ANXA4 SNX29 SULT1C2 GAREM1

1.60e-0419411757002937e8903e037332a215d00fbc7c7843b33f2
ToppCellLPS-IL1RA-Endothelial|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

FAT4 PDE3B ZNF423 PIK3C2B MCF2L

1.60e-04194117543f92b0533e26633dc94cce554045d641ef8fd76
ToppCellLPS-IL1RA-Endothelial-Endothelial-Gen_Cap|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

FAT4 PDE3B ZNF423 PIK3C2B MCF2L

1.60e-0419411750b9cd96fa0b616da7cc90e92ff71157e9bba518f
ToppCellLPS-IL1RA-Endothelial-Endothelial|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

FAT4 PDE3B ZNF423 PIK3C2B MCF2L

1.60e-0419411751d39d968730a7e85b6161c1c8a6bd38afe9bcad7
ToppCellLPS_only-Endothelial|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

FAT4 PDE3B ZNF423 PIK3C2B MCF2L

1.60e-04194117558f069efdefa0366033764446b9d6ffd4a17807e
ToppCellLPS_only-Endothelial-Endothelial|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

FAT4 PDE3B ZNF423 PIK3C2B MCF2L

1.60e-041941175bfd92ec75facb0ba55c31e5f2e089d983b3d0169
ToppCellproximal-3-Endothelial-Vein|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

DNHD1 FAT4 NUAK2 PIK3C2B ZNF341

1.64e-041951175c81eb541c15b866f9b6ca6a5f1751c5f1243f4fb
ToppCellproximal-Endothelial-Vein-3|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

DNHD1 FAT4 NUAK2 PIK3C2B ZNF341

1.64e-041951175df00f94facc5d6107aac83cef3c64fefc7f8e562
ToppCellproximal-Endothelial-Vein|proximal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)

DNHD1 FAT4 NUAK2 PIK3C2B ZNF341

1.64e-0419511750aebdd635a956dd2367883c1cf73d73ce9790635
ToppCellFetal_29-31_weeks-Mesenchymal-matrix_fibroblast_2_cell-D062|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

FMOD RYR2 MEOX1 PIEZO2 OSR1

1.68e-041961175525d6c8a277364e624e7cc586275f8a891436b57
ToppCellCOVID-mDC2|COVID / Condition, Cell_class and T cell subcluster

IGSF6 HLA-DRA MAGEF1 TLR10 ST18

1.68e-041961175bb13926bb664be917017edb0ce7f184abe31744b
ToppCellCOVID-mDC2-|COVID / Condition, Cell_class and T cell subcluster

IGSF6 HLA-DRA MAGEF1 TLR10 ST18

1.68e-0419611756d02a4c5c19be7e036150cf945585cf5a773bc87
ToppCell(7)_Macrophage|World / Spleen cell shreds - cell class (v1) and cell subclass (v1)

IGSF6 HLA-DRA GPR85 SLC46A1 PIEZO2

1.68e-041961175f1c822860d2a0bae84b0263b0151185756423e0f
ToppCellfacs-Heart-RA-3m|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

PDE3A RPL37 PIEZO2 TM9SF2 PAN3

1.72e-041971175940cf1e54d7c820e04946258a8b784f35c6a144c
ToppCellBrain_organoid-organoid_Kanton_Nature-Organoid-2M-IPC_like|Organoid-2M / Sample Type, Dataset, Time_group, and Cell type.

UNC5A EMX2 RNF24 ZBTB18 ST18

1.76e-0419811756d12ecaa9532c134d9c4562534dcb59a6420b4d3
ToppCellfacs-Tongue-nan-3m-Epithelial|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RPL37 CSE1L TM9SF2 ABCD3 PAN3

1.76e-0419811752f03f8897dd7cce6d8296638e14e11ec16bcf624
ToppCellBrain_organoid-organoid_Kanton_Nature-Organoid-2M-IPC_like-IPs_and_early_cortical_neurons|Organoid-2M / Sample Type, Dataset, Time_group, and Cell type.

UNC5A EMX2 RNF24 ZBTB18 ST18

1.76e-0419811757943e4f67c3d6efb5c8b00aa0ff3cfe7be10c48d
ToppCellControl-PLT_4|Control / Disease Group and Platelet Clusters

ARHGAP32 RYR2 TIPARP ZNF766 USP15

1.76e-041981175387fd3037fd52e4d4c42de0588767e58af228b59
ToppCellfacs-Tongue-nan-3m|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RPL37 CSE1L TM9SF2 ABCD3 PAN3

1.76e-041981175f2a4057f038ef7225a5b98a7ab068c30dff4eadd
ToppCellfacs-Tongue-nan-3m-Epithelial-nan|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

RPL37 CSE1L TM9SF2 ABCD3 PAN3

1.81e-0419911758d50e1ee58710d896c0204937331d9f4dcd38de0
ToppCellFetal_brain-fetalBrain_Zhong_nature-GW09|fetalBrain_Zhong_nature / Sample Type, Dataset, Time_group, and Cell type.

HLA-DRA NDST4 NUAK2 EMX2 ST18

1.81e-041991175399e73d45638848e68edda120316ceff04d98680
ToppCell10x3'2.3-week_17-19-Mesenchymal_fibro-stroma-arteriolar_fibroblast|week_17-19 / cell types per 3 fetal stages;per 3',per 5'

FAT4 FMOD PIEZO2 KCND2 OSR1

1.81e-04199117595d95e9b7bd3933188998ae94986213eb0f1e5ea
ToppCellTracheal-NucSeq|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations

USP34 ARHGAP32 DYM WDPCP PAN3

1.81e-04199117594b94b17ca18b8dc27b91da1f2ccf89e03cc7035
ToppCellBronchial-10x5prime-Stromal-Fibroblastic-Fibro_myofibroblast|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations

FAT4 FMOD PIEZO2 CPT1C OSR1

1.81e-04199117521335475bbfbad8a6943b8076a6c1c67f3eec5d3
ToppCellTCGA-Stomach-Primary_Tumor|TCGA-Stomach / Sample_Type by Project: Shred V9

ATAD5 URB2 NFE2L3 CSE1L POLR1B

1.81e-04199117538f1f612b29feb868322999ceeda78e52447ec4f
ToppCellTransverse-Macrophage-LYVE1_Macrophage|Macrophage / Region, Cell class and subclass

DNHD1 GBE1 ZNF616 PPIP5K1 ZNF700

1.81e-041991175fd75dccb37d96448edf72b7d042b06833d4ead24
ToppCellBronchial-10x5prime-Immune_Myeloid-Myeloid-Megakaryocyte|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations

PDE3A GBE1 PIEZO2 ZNF766 ZNF700

1.81e-0419911756e7f7214317f2af2ba8523df9896f54b7294d58a
ToppCellBronchial-10x5prime-Immune_Myeloid-Myeloid|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations

PDE3A GBE1 PIEZO2 ZNF766 ZNF700

1.81e-0419911755f499595597c10857bba8272f62afe4d32d733ac
ToppCellTCGA-Stomach-Primary_Tumor-Stomach_Adenocarcinoma|TCGA-Stomach / Sample_Type by Project: Shred V9

ATAD5 URB2 NFE2L3 CSE1L POLR1B

1.81e-041991175b10698aee2e6c17bc559eb4f723024141f914b90
ToppCellTracheal-NucSeq-Stromal-Chondrocytic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

PDE3A ADCY2 TIPARP PIEZO2 TIAM1

1.85e-042001175b5a54b9baf79aea01f76a161f0a39bbe87eb4945
ToppCellTracheal-NucSeq-Stromal-Chondrocytic-Chondrocyte|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

PDE3A ADCY2 TIPARP PIEZO2 TIAM1

1.85e-042001175f5bd0b30e478dac09f68c46b0781f5f2e7e3c693
ToppCellTracheal-NucSeq-Epithelial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

ARHGAP32 MYO5B MCF2L GAREM1 TMEM63A

1.85e-042001175d3af0a706baf66e3f32e67b17dcfc31e5b32ce0e
ToppCellTracheal-10x3prime_v2-Stromal-Peri/Epineurial_-NAF_epineurial|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations

FMOD ADNP SBF1 TIAM1 GAREM1

1.85e-04200117524e13b6d9d2d8b29df1f02544ea9c50084d9e75c
ToppCellTracheal-NucSeq-Epithelial-Epi_submucosal-gland|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

ARHGAP32 MYO5B MCF2L GAREM1 TMEM63A

1.85e-0420011750eb9ad8c0373bcc62029ec21c590ed03aaacd039
ToppCellParenchymal-NucSeq-Stromal-Fibroblastic-Fibro_adventitial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

PDE3A PIEZO2 KCND2 OSR1 HAS1

1.85e-04200117574e74123ea7bf38d337a3a0248a6a51437c6ab42
ToppCellTracheal-NucSeq-Stromal-Fibroblastic-Fibro_peribronchial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

FAT4 PDE3B NDST4 IRS1 RYR2

1.85e-04200117558b38f9a484ee94191091a0659ed62ebed2d4a14
DrugHexamethonium dibromide dihydrate [55-97-0]; Down 200; 10uM; MCF7; HT_HG-U133A

CDK10 MAGEF1 CSE1L SBF1 MTRR AP1G2 RNF24 TMEM63A

7.59e-0619811581482_DN
Drugtryptophan pyrolysate

DYM GLB1 SULT1C2 PKD2 HAS1

9.37e-06561155CID005284475
DrugM-HN

PDE3A PDE3B RYR2 RYR3

1.75e-05311154CID000015450
DrugInocor (TN)

PDE3A PDE3B

2.53e-0521152CID000656683
DrugRS-1893

PDE3A PDE3B

2.53e-0521152CID000128386
Drugromifidine

PDE3A PDE3B MTRR

3.46e-05131153CID000071969
DrugAC1OAGFW

ARHGAP32 IRS1 SBF1 TIAM1 PIK3C2B CLTC MCF2L

4.22e-051841157CID006857352
DrugGvapspat amide

FMOD RYR2 RYR3

5.46e-05151153CID000125015
DrugMephenesin [59-47-2]; Down 200; 22uM; HL60; HT_HG-U133A

USP34 IFT27 ARHGAP32 PDE3B TUBGCP5 CDK10 TMEM63A

6.50e-0519711572342_DN
DrugO-B-F

ARHGAP32 PDE3A PDE3B

6.70e-05161153CID000141025
DrugNitrendipine [39562-70-4]; Down 200; 11uM; MCF7; HT_HG-U133A

USP34 RYR2 SBF1 MSL3 MCF2L RNF24 TMEM63A

6.71e-0519811575405_DN
DrugSulfathiazole [72-14-0]; Up 200; 15.6uM; HL60; HG-U133A

ARHGAP32 APPBP2 RAP1GAP ZNF224 CDK10 AP1G2 MASP2

6.71e-0519811571963_UP
DrugNorethindrone [68-22-4]; Up 200; 13.4uM; MCF7; HT_HG-U133A

PDE3B FMOD SNX29 MEOX1 PKD2 PISD TMEM63A

6.93e-0519911577414_UP
DrugDanazol [17230-88-5]; Up 200; 11.8uM; PC3; HG-U133A

ARHGAP32 SNX24 PIEZO1 SBF1 PISD SNX15 RNF24

6.93e-0519911571954_UP
DrugSulfadiazine [68-35-9]; Up 200; 16uM; MCF7; HT_HG-U133A

ATAD5 GPR85 CDK10 PIEZO2 AP1G2 MCF2L TMEM63A

6.93e-0519911575523_UP
Drugprochlorperazine dimaleate salt; Down 200; 10uM; MCF7; HT_HG-U133A

USP34 PDE3B ATAD5 CDK10 SBF1 SNX15 MCF2L

6.93e-0519911575575_DN
DrugLidoflazine [3416-26-0]; Down 200; 8.2uM; PC3; HT_HG-U133A

FAT4 RYR2 CSE1L TIAM1 MSL3 MCF2L TMEM63A

6.93e-0519911575804_DN
DrugSureCN4406168

PDE3A PDE3B

7.56e-0531152CID011502028
DrugSureCN4395097

PDE3A PDE3B

7.56e-0531152CID011610011
DrugSureCN4401117

PDE3A PDE3B

7.56e-0531152CID011718172
DrugSureCN4402206

PDE3A PDE3B

7.56e-0531152CID011516917
DrugWIN 62582

PDE3A PDE3B

7.56e-0531152CID005487388
DrugSureCN4397066

PDE3A PDE3B

7.56e-0531152CID011538627
DrugSureCN4401121

PDE3A PDE3B

7.56e-0531152CID011611819
Drugcis-diammineplatinum(II

RYR2 RYR3

7.56e-0531152CID000159790
DrugSureCN4404748

PDE3A PDE3B

7.56e-0531152CID011502895
Drug2-hydroxyheptanoic acid

RYR2 RYR3

7.56e-0531152CID002750949
DrugSureCN4411688

PDE3A PDE3B

7.56e-0531152CID011523192
Drug8N3-cADPR

RYR2 RYR3

7.56e-0531152CID000127713
Drugaminodantrolene

RYR2 RYR3

7.56e-0531152CID009570289
DrugSureCN4405038

PDE3A PDE3B

7.56e-0531152CID011546172
DrugSureCN4405912

PDE3A PDE3B

7.56e-0531152CID011682920
Drugpelrinone

PDE3A PDE3B

7.56e-0531152CID000055919
DrugSureCN4398032

PDE3A PDE3B

7.56e-0531152CID011532088
Drug2-hydroxycarbazole

RYR2 RYR3

7.56e-0531152CID000093551
DrugSureCN4406373

PDE3A PDE3B

7.56e-0531152CID011711104
DrugSureCN4394894

PDE3A PDE3B

7.56e-0531152CID011711103
Drugsilicon;titanium

ARHGAP32 DYM

7.56e-0531152CID006336553
DrugSureCN5995113

PDE3A PDE3B

7.56e-0531152CID011640499
DrugCHEMBL219123

PDE3A PDE3B

7.56e-0531152CID016102624
Druggermitrine

PDE3A PDE3B

7.56e-0531152CID000011217
DrugSureCN4411840

PDE3A PDE3B

7.56e-0531152CID011567407
DrugSureCN4401113

PDE3A PDE3B

7.56e-0531152CID011544858
DrugRyanodyl 3-(pyridine-3-carboxylate

RYR2 RYR3

7.56e-0531152CID005748312
DrugSureCN4405883

PDE3A PDE3B

7.56e-0531152CID011516351
DrugSureCN4407211

PDE3A PDE3B

7.56e-0531152CID011553351
DrugSureCN4401096

PDE3A PDE3B

7.56e-0531152CID011710801
Drugzaprinast

PDE3A PDE3B PDE6A RYR2 RYR3 GLB1

8.20e-051411156CID000005722
DrugAC1L18MO

LCTL GLB1

1.51e-0441152CID000000168
DrugPCB74

RYR2 RYR3

1.51e-0441152CID000036218
DrugR 80122

PDE3A PDE3B

1.51e-0441152CID009571043
Drugisomazole

PDE3A PDE3B

1.51e-0441152CID000055689
DrugUK-1745

PDE3A PDE3B

1.51e-0441152CID003035852
Drug148504-47-6

RYR2 RYR3

1.51e-0441152CID006444275
DrugSC 38249

RYR2 RYR3

1.51e-0441152CID000134834
Drugnanterinone

PDE3A PDE3B

1.51e-0441152CID000071305
DrugAC1L1U7A

RYR2 RYR3

1.51e-0441152CID000035682
DrugEMD 57033

PDE3A PDE3B CLTC

2.07e-04231153CID000187079
Diseasecongenital myopathy 1A (implicated_via_orthology)

RYR2 RYR3

4.20e-0531112DOID:3529 (implicated_via_orthology)
Diseasemalignant hyperthermia (implicated_via_orthology)

RYR2 RYR3

4.20e-0531112DOID:8545 (implicated_via_orthology)
DiseaseAlcoholic Intoxication, Chronic

AGO2 HLA-DRA SLC46A1 TIPARP AGO1 ST18 IPO11

7.17e-052681117C0001973
Diseaseanencephaly (is_implicated_in)

NUAK2 MTRR

8.37e-0541112DOID:0060668 (is_implicated_in)
Diseasepulmonary hypertension (biomarker_via_orthology)

PDE3A RYR2 RYR3 HAS1

2.41e-04801114DOID:6432 (biomarker_via_orthology)
DiseaseNEPHRONOPHTHISIS 2

ZNF423 CEP83

3.87e-0481112C1865872
DiseaseHyperhomocysteinemia

SLC46A1 MTRR

7.54e-04111112C0598608
DiseaseCiliopathies

RPGRIP1 ZNF423 WDPCP PKD2

8.06e-041101114C4277690
DiseaseConnective Tissue Diseases

PIEZO2 PKD2

1.06e-03131112C0009782
DiseaseHermansky-Pudlak syndrome (implicated_via_orthology)

CCZ1B CCZ1

1.24e-03141112DOID:3753 (implicated_via_orthology)
DiseaseMeckel-Gruber syndrome

RPGRIP1 WDPCP

1.43e-03151112C0265215
Diseaseposterior cingulate cortex volume measurement

NDST4 ADCY2

1.84e-03171112EFO_0010324
Diseaseascending aortic diameter

ATAD5 RYR2 PIEZO2 USP15

1.96e-031401114EFO_0021787
DiseaseMeckel syndrome type 1

RPGRIP1 WDPCP

2.06e-03181112C3714506
Diseasesusceptibility to mononucleosis measurement

FAT4 ADCY2 RYR2

2.27e-03691113EFO_0008403
DiseaseCannabis use, age at onset

ZNF423 RYR2

2.30e-03191112EFO_0004847, EFO_0007585
Diseasebipolar disorder (is_marker_for)

RAP1GAP HLA-DRA

2.30e-03191112DOID:3312 (is_marker_for)
DiseaseOsteochondrodysplasias

GLB1 PISD

2.30e-03191112C0029422
Diseasevital capacity

USP34 PDE3A SNX24 ATAD5 PIEZO1 CDK10 MAGEF1 RYR2 CSE1L PIK3C2B ZNF341 CEP83

2.40e-03123611112EFO_0004312

Protein segments in the cluster

PeptideGeneStartEntry
QFRFYRHVAELLINH

URB2

386

Q14146
LYEIVRKHIYREHFQ

ADNP

176

Q9H2P0
SKRRFLHYFEGIHLD

ATAD5

1816

Q96QE3
MFSLFIENRYLHLLH

LINC00158

1

P58513
TDIIHLDAQRLHYYR

ABCF1

516

Q8NE71
TVKDFLTNHYLHFLR

FAT4

3721

Q6V0I7
LVAFRARYHLVDKEH

AGO1

806

Q9UL18
RLKLRLTYDHFHQSV

AP1G2

756

O75843
RQIEYFRSLLDEHHI

SPECC1L

461

Q69YQ0
EQLIKHAVYLARDHF

APPBP2

266

Q92624
LRYEHTFLKSEFEHQ

CEP83

151

Q9Y592
EYVRALHELIRNHFS

DNHD1

851

Q96M86
NRNHLLHVFDEYKRI

ANXA4

201

P09525
SYLKEFIHILYFRHL

ACTR10

66

Q9NZ32
AHLVAFRARYHLVDK

AGO2

806

Q9UKV8
QFYRDSHTLHEVLRK

RAD17

231

O75943
RQLFLKYILAHFRGH

RIMBP3B

196

A6NNM3
RQLFLKYILAHFRGH

RIMBP3C

196

A6NJZ7
NHYILHNSFFRREIK

TIPARP

386

Q7Z3E1
LEAEFAHHNYLTRLR

MEOX1

186

P50221
KHFDLFVRFLAEYHD

MSL3P1

406

P0C860
DFRLKYENELALHHS

KRT26

171

Q7Z3Y9
RLFTFRHHRSIVQLY

SLC46A1

241

Q96NT5
FSKLRHLERLYLDHN

FMOD

151

Q06828
NILHIKQLYHSDEFR

LIPN

291

Q5VXI9
FELKQFDRKHHTYIL

MAGEF1

131

Q9HAY2
DLRQHRALLTFYHVT

IPO11

141

Q9UI26
DYLFRKELRHFLKHG

MTRR

586

Q9UBK8
DFDYLRFLQKRFRHH

GLB1

196

P16278
DIILLRELHVNHYRF

LCTL

96

Q6UWM7
LINLDHVEFKHFRFL

PDE3A

886

Q14432
LLHLDHVEFKRFRFL

PDE3B

871

Q13370
ERQFHKALYTVRAFL

PDE6A

256

P16499
DLHFIREGHRYKFVN

GAREM1

261

Q9H706
QKLHDLYHDIFSRLR

NFE2L3

636

Q9Y4A8
LKHFDLFLRFLAEYH

MSL3

481

Q8N5Y2
HYFIDRDGLLFRHVL

KCTD4

76

Q8WVF5
IFRHILNFYRTGKLH

KCND2

91

Q9NZV8
LIKIHYRYLSTIHDR

TUBGCP5

926

Q96RT8
ISRIEYVHTKNFLHR

CSNK1A1L

121

Q8N752
YYRDHNVELSKLLHR

NDST4

841

Q9H3R1
AIHYLSFQRHIIFLL

TMEM63A

136

O94886
KHLVALYTRDEHFAI

IRS1

81

P35568
RSYEDFRVLDKHLHL

ARHGAP32

171

A7KAX9
FRVLDKHLHLCIYDR

ARHGAP32

176

A7KAX9
GRHFTKSYNLLIHER

OSR1

181

Q8TAX0
LDKTKHQLRYYDHRV

SBF1

1786

O95248
TRRAHFSKYLFHLIV

PIK3C2B

671

O00750
GDRYLLKLFRDHLFH

PAN3

806

Q58A45
DRHLFALYIVSRFLH

CPT1C

651

Q8TCG5
RFFHHLLRYQRFEKA

WDPCP

576

O95876
RLFHKLFSHYNQFIR

CHRNA6

36

Q15825
EHFLARSLKNEELYH

ADCY2

866

Q08462
RVFHDRLINNEDKHY

DNAH6

2331

Q9C0G6
RLINNEDKHYFHVIL

DNAH6

2336

Q9C0G6
HYARRQFHLTDDDLL

GBE1

561

Q04446
FHQLYREKVEVFRAL

IFT27

171

Q9BW83
RIFQEIAQELYHKRH

IGSF6

201

O95976
ALLYKRDLFEQFRTH

DYM

556

Q7RTS9
RFDLRFVVIHDRYDH

DMAP1

166

Q9NPF5
LQYLHRNFIIHRDLK

CDK10

151

Q15131
ERLEKFFHRYLQTLH

CCZ1

166

P86791
ERLEKFFHRYLQTLH

CCZ1B

166

P86790
VFLPREDHLFRKFHY

HLA-DRA

161

P01903
HLVAQSLFAYLEHRR

HAS1

66

Q92839
EEIYHFHNRIFLREL

MCF2L

686

O15068
RLRLYFTHFDLELSH

MASP2

56

O00187
LAIAHHRFYTKRLTF

GPR85

121

P60893
LLRLEHAFEKNHYVV

EMX2

166

Q04743
EFIRLYQSLLHRHRK

DNAH9

3046

Q9NYC9
EQEELLKFHYHTLRL

RYR2

1646

Q92736
YLLKIVNFSRLIFHH

TAS2R20

106

P59543
YLLKIVNFSRLIFHH

TAS2R36

106

P0DTE0
LDHYLRREALSIHVF

RPGRIP1

861

Q96KN7
KHELQRFYSLRHIAS

SNX29

96

Q8TEQ0
IYRRYTEFRSLHHKL

SNX29

691

Q8TEQ0
TIKLEHVHFRVFYIQ

TLR10

301

Q9BXR5
DEKRKYSHFQHLLYR

HPS3

281

Q969F9
HLKIVYRRFRHGFRE

RPL37

66

P61927
RQLFLKYILAHFRGH

RIMBP3

196

Q9UFD9
TARIYRKHFLGKEHF

RAP1GAP

86

P47736
LIRLRHQAHKEFYAY

RNF24

46

Q9Y225
KHNLRHRYEFLETLG

NUAK2

46

Q9H093
HNTYKELDRFLLEHL

ST18

321

O60284
FRKLVEHLHNFILFR

ABCD3

296

P28288
KHELIEFRRIAAYLF

CLTC

1501

Q00610
RKFHHFEAFRLLAQY

CLVS2

61

Q5SYC1
FSIHRRLHLTKRFYE

ZNF707

331

Q96C28
KAFRYVKHLQIHERT

ZNF700

481

Q9H0M5
KFFRREHYLKLHAHI

ZNF341

601

Q9BYN7
HHRENVFLSYQDKRI

VSIG8

71

P0DPA2
RTAHSLFKRYRHEFK

CSE1L

151

P55060
DIENLYFREIQKHLH

ZNF616

81

Q08AN1
YFREIQKHLHDLEFQ

ZNF616

86

Q08AN1
DHSAHYLRLKFLIEN

TIAM1

801

Q13009
RKHFVEKRYSEFHAL

SNX24

31

Q9Y343
FRHSYLHLAENYLIR

UBA7

881

P41226
QEDLMRFHYHTLRLY

RYR3

1551

Q15413
RHQILFLFYEDIKRD

SULT1C2

186

O00338
VEDLHHYRNLSEFFR

PISD

156

Q9UG56
LYRHIRKFHCELVNS

ZBTB18

481

Q99592
RKLHGDLAYTHRNLF

SNX15

56

Q9NRS6
KAFRLHYQLTEHQRI

ZNF546

336

Q86UE3
HYFHDRFLELTDLKS

PIEZO2

806

Q9H5I5
IVTDIYNHRFHRIFA

USP15

521

Q9Y4E8
FHYIKRLLETLFVHR

TECR

136

Q9NZ01
EILEIRIHKLHYFRS

PKD2

491

Q13563
EHERTFLLEYHNRVK

SNX6

211

Q9UNH7
LFRHQRIHTGEKLYE

ZNF585A

201

Q6P3V2
RVLHFKDSYHNLRLS

UNC5A

641

Q6ZN44
HERDTFYIFNHVDIK

TM9SF2

201

Q99805
FFRYNSTLLRHQKVH

ZNF547

386

Q8IVP9
YRFHAIAKHKRNITE

TAS2R8

156

Q9NYW2
LLQRRVFLSHYYLHV

PIEZO1

1296

Q92508
SFIRLSYLKRHEQIH

ZNF423

146

Q2M1K9
LFNRIAYLARHEKVH

ZNF766

251

Q5HY98
LKTHLEAFRRRFAYH

USP34

1171

Q70CQ2
AFHRDTFHFLREEKI

ZNF224

51

Q9NZL3
VADKLNFIRYLSHFR

POLR1B

456

Q9H9Y6
VLFRYLHSHHFLELV

VIRMA

671

Q69YN4
LLRLHSTFRHDLKIY

PPIP5K1

561

Q6PFW1
FRQLAYLVEHKRIHT

ZNF789

266

Q5FWF6
LHNLKVRFLESNHIY

MYO5B

86

Q9ULV0